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ABSTRACT
The Use of the Reducing Agent N-(2-Mercaptopropionyl)glycine to Detoxify
Oxidized Lipids in Atherosclerotic Lesions
Nason P. Schooler
December 1, 2008
The leading cause of death in the United States is cardiovascular disease, a result
of atherosclerosis. The reducing agent N-(2-Mercaptopropionyl)glycine (MPG) as been
found to be an effective antioxidant therapy in a number of conditions, and our
hypothesis is that it will be an effective agent in the detoxification of oxidized lipids in
atherosclerosis. Our results indicate some protective effect, along with some toxicity at
high doses, with refinement of the experimental model necessary before results can be
conclusive. Nevertheless, antioxidant and aldehyde-quenching agents in general have
been shown to be of benefit in the detoxification of oxidized lipids, and MPG is still
therefore a good candidate. Since this is yet another mechanism used to combat the
disease, we hypothesize that such reducing agents will complement other therapies quite
effectively, providing an even more effective means of preventing the onset, as well as
reversing the progression of atherosclerosis.
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INTRODUCTION

Cardiovascular disease (CYO) is the leading cause of death in the US, the major
contributor being coronary artery disease brought on by the onset of Atherosclerosis. 4
Atherosclerosis is the pathology behind the two major components of cardiovascular
disease; vascular disease leading to stroke, and coronary artery disease leading to heart
attacks. The main characteristic of an atherosclerotic lesion is the deposition of
cholesterol in medium to large arteries. In these critical vessels, the cholesterol deposits
can grow over time, until the blood now is hindered by the resulting occluded lumen, and
heart attack and stroke result when the flow is completely blocked. Usually an actual
rupture of a mature atherosclerotic plaque is the cause of sudden-onset heart attack or
stroke. 5
One of the most important factors influencing the development of atherosclerosis
is the amount of cholesterol in circulation. This relationship between cholesterol and the
development of atherosclerosis was recognized early on due to the genetic disorder
Familial hypercholesterolemia. Heterozygote patients with this trait have a reduced
number of LDL (low density lipoprotein - a common form of cholesterol packaged for
transport in the bloodstream) receptors, and homozygous individuals have no LDL
receptors. This is devastating particularly in the case of hepatic cells, which are
responsible for removing cholesterol from the bloodstream. Thus, these individuals have
high levels of circulating cholesterol, and correspondingly short lifespan, due to early-

onset atherosclerosis and subsequent cardiovascular disease. Furthermore, cholesterollowering therapy has been found to greatly alleviate, and in some cases reverse the
progression of atherosclerosis. Key among these are the statins - a group of compounds
targeting the key regulatory enzyme in cholesterol synthesis: HMG-CoA reductase.6

The Anatomy of a Blood Vessel
Before we begin our discussion of the features and development of atherosclerotic
lesions, it will help to describe the basic features of a normal artery. Figure 1 depicts the
three principal layers which surround the arterial lumen. The intima consists of a
monolayer of vascular endothelial cells on a second layer of mostly smooth muscle cells
in a substrate of extracellular matrix . The media is made up of further layers of smooth
muscle cells, and the adventitia, consisting
Internal
Elastic Lamina

/

/

External
Elastic Lamina

of collagen, fibroblasts, smooth muscle cells
and elastin. Thin layers of elastin also
separate the other layers, making up the
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Figure 1 - The layers of tissue in an artery. Th e intima is closest to th e
lumen, while the Adventiti a makes up th e outer su rface of the vessel.

internal and external elastic laminas.

The Development of Atherosclerotic Lesions
Despite the fact that the relationship between cholesterol in circulation,
cholesterol deposits in arteries and atherosclerosis is well known, the fundamental
genesis of these deposits has not been definitively identified. What is known for certain
is that fatty streaks - small deposits of cholesterol in the intima - begin forming at an
early age in the arteries of most denizens of developed societies. Preceding the
appearance of these fatty streaks, is a thickening of the intima - termed type I lesions,
these instances of thickening are thought to be an adaptive response to shear stresses
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along the vessel wall and to tensile stresses against the wall. They are denoted as areas of
eccentric thickening, as opposed to uniform thickening of the intima, called diffuse
thickening, which does not directly correlate with atherosclerosis. While atherosclerotic
lesions form at these sites, such areas of eccentric thickening occur whether or not
atherosclerosis is present. The same stresses that result in eccentric thickening due to
CoI'OlJary

irregularities in the fluid flow also

artery at

l~i(Jn ·pron~ locatioo

apparently contribute to cholesterol
deposition in the intima, if serum
cholesterol levels are high enough.
Thus lesions form earlier at these
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locations than elsewhere in the arteries,
and they are therefore associated with
the initial appearance of fatty streaks,
and subsequently the classic locations

~
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of advanced lesions.7
Figure 2 shows the six
morphological stages 3 recognized as
making up the classic development of an

Figure 2 - The six types of lesions in the progression of atherosclerosis .

(From Stary et al ' )

atherosclerotic lesion. Following the adaptive thickening of the intimal smooth muscle
region, There is an increase in the concentration of deposited plasma components.
Proteins, HDL and LDL, along with most plasma constituents, deposit within the intima
throughout the arteries in proportion to their concentrations in the bloodstream and their
molecular weights. In regions of eccentric thickening, however, macrophages, LDL, and
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the other plasma components are more concentrated. Since the endothelial layer directly
adjacent to the arterial lumen is very amenable to such deposition, and since a large
contributor seems to be the natural fluid flow in the lumen, it naturally follows that areas
which thicken in response to excess tensile stress will accumulate additional material as a
result of such stress. Thus, in these areas of eccentric thickening in normal healthy
arteries the seeds of atherosclerosis are sown. The essential players are there - excess
cholesterol in the form of LDL and macrophages to take them up and form foam cells.
The current predominant view is that accumulation ofLDL leads to inflammation, thus
initiating the onset of atherosclerosis. 8 The oxidization of LDL and the subsequent
involvement of inflammation and macrophages in foam cell formation are key factors
determining whether a fatty streak will remain benign, or develop into more advanced
types of atherosclerotic lesions. Such oxidization can be the target for a variety of
different interventions, which will be discussed below.
Type II lesions are characterized by the formation of fatty streaks made up of
macrophages that have taken up excessive amounts of lipids (foam cells). Fatty streaks
are not inherently pathologic, and may never tum into type III lesions, or they may even
regress on their own. In fact, each of the six types of lesions represent inherently stable
entities which may remain unchanged for long periods of time, or may continue on to
become more advanced lesions. 9 In the event that the fatty streaks continue to grow due
to the accumulation of foam cells, type III lesions become evident. These are
characterized by the appearance of extracellular lipid patches, which are the result of
macrophage necrosis, and can readily accumulate by the age of 10 years. By the mid 30's
they can account for one third of the surface area of the aorta. 10

4

Type IV lesions are considered full atheromas, conisisting of a large, contiguous
area of extracellular lipids within the intima. Eventually, these areas can develop a hard,
fibrous cap, at which point they are type V fibroatheroma lesions. Such lesion caps form
mostly in the mid 30's to mid 40's, the vessels involved being predominantly abdominal
aorta, coronary and carotid arteries. The main distinguishing factor between types IV
and V is that of new structural fibrous material forming prominent connective tissue that
was not present before. This tissue can be extensive, composed of several layers of
lesions that form in a step-by-step fashion. Following the formation of an initial type V
lesion, the flow geometry may change significantly, resulting in new deposition of tissue
in a nearby, partially overlying area. This process can occur repeatedly, together with
multiple thrombotic events and micro-hemorrhages in capillaries throughout the lesion,
resulting in an irregularly stacked conglomeration of overlapping extracellular lipid cores
separated by fibrous walls. By the time a lesion has reached type V, the original structure
of the vessel has become significantly altered, resulting in a significant rearrangement of
smooth muscle and endothelial cells, as well as rearrangement and formation of new
areas of connective tissue. 3
The most devastating pathologies arise from Type VI lesions, which arise when
the shoulder region between the fibrous cap and the normal artery wall ruptures. Type VI
lesions often contain evidence of previous fissuring in this area which has subsequently
been patched over. At this point, the lesion is in danger of significant rupture and
resulting thrombosis and occlusion of the artery at any time.
The goal of preventive measures and even therapy is to intervene before lesions
progress to this final stage. As would be naturally expected, earlier is better, and simple
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modifications of the diet can result in complete reversion of type I, II and III lesions. 9
One of the earliest contributing factors in the development of foam cells is the appearance
of oxidized lipids. Thus much research has been done to elucidate the underpinnings of
this process, as well as where lipids are oxidized, and how the deleterious interaction with
macrophages takes place. II

The Role of Oxidized Lipids
LDL has not been found to be an effective contributor to atherosclerosis in its
normal state. Macrophages have been found to be quite reluctant to take up normal LDL.
However, the LDL can become modified into a form that is highly atherogenic. Once
LDL is oxidized, macrophages take it up approximately 40 times faster than normal LDL
- and by a different class of receptors, called scavenger receptors. 12 While acetylation
was carried out in initial in vitro experiments 13 to demonstrate this rapid uptake, this
modification is not involved in vivo. Oxidative modification ofLDL does happen in the
living organism however, and subsequent investigations showed that macrophages took
up such LDL as readily as the
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Figure 3 - The Oxidative Modification Process
LOL trapped in the intima becomes oxidized by vascular smooth muscle celis, endothelial celts and
macrophages. A. This attracts more macrophages due to thei r chemotactic attraction to oxidized
lipids. B. Monocytes are also prevented from leaving the intimal space. C. Nondeg radable
oxidized lipids accumulate in the Iysosomes of macrophag8s, which become foam cells. D.
Endothelial cells also become injured and dysfunctional due to the presence of oxidized LDL. E.
Accumulation of indigestible lipids in foam cells eventually leads to apoptosis and necrosis. (From

Diaz et a.)'
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macrophages, by preventing
macrophages from leaving

the intima, and by aiding the attraction of circulating monocytes into the intima in the
first place. 15 The role of oxidization of LDL in the development of atherosclerosis is
summarized in Figure 3.

When LDL is trapped in the intima and becomes oxidized by surrounding cells,
the lysine residues of apolipoprotein-B-l 00 (one of the protein components of LDL)
become more negatively charged. Haberland et al. have demonstrated that such
malondialdehyde-induced modifications result in crosslinks which make the molecule
amenable to scavenger-receptor uptake,16 eventually leading to the formation of foam
cells. I? LDL can also be oxidatively modified independently of apolipoprotein-B-lOO.
Such minimally modified LDL induces the production of monocyte chemotactic proteins
in endothelial cells and also smooth muscle cells 18 , and overall inducing a proinflammatory response in the tissue. 19 Without the necessary chemotaxis receptor, the
macrophages of mice do not respond accordingly, and the mice have been found to be
resistant to atherosclerosis. 2o Monocytes and T-lymphocytes are also highly chemotactic
in response to more heavily oxidized LDL21 (termed oxLDL), which also stimulates the
production of auto-antibodies and immune complexes which facilitate macrophage
ingestion ofLDL.22 Inflammation can also promote further oxidation ofLDL, thus
expanding the lesion.
Detoxification of Oxidized Lipids to Treat Atherosclerosis
Since oxidation of LDL has been found to be quite deleterious and inherently
foundational in the etiology of atherosclerosis, the search for effective methods to
detoxify this substance has been and continues to be a major field of study.23
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Current Therapies Using Antioxidants and Reducing Agents
Vitamin E has been one of the most thoroughly investigated antioxidant therapies
for atherosclerosis. While a number of small clinical trials have shown promising results,
all large-scale clinical trials have shown no beneficial effect of vitamin E in the treatment
of heart disease. 24 In several animal models, and in certain special conditions, such as
12/15-lypoxygenase gene inhibition, vitamin E has been shown to be quite beneficial in
this regard. 25 It seems that in certain groups, for instance those in which oxidative stress
is a system-wide pathology, such antioxidant administration can be quite beneficial.
Overall, vitamin E has been proven to be anti-oxidant or pro-oxidant or even neutral in
atherogenesis, depending on myriad other factors. 26
Other antioxidants which have been assayed for therapeutic intervention in
atherogenesis include Glutathione27 , Probucol and several analogs, individual
polyphenols and mixtures of polyphenols, and combination therapy using vitamin E in
conjunction with Selenium, vitamin A, or vitamin C. 23 The role of human alto-ketoreductase in protection against toxic aldehydes has also been examined,28 with an eye
towards potential therapies involving similar adehyde reduction. Several types of
aldehyde groups resulting from lipid peroxidation have been lumped together into the
category of reactive carbonyl species (RCS). These include a,p-unsaturated aldehydes,
di-aldehydes, and keto-aldehydes. Since RCS are widely prevalent in atherosclerotic
lesions despite the presence of large amounts of antioxidants such as vitamins C and E in
the vessel wall, an alternative strategy has been developed to detoxify them - namely, the
use of agents which sequester and thus nullify carbonyls directly.29 These sacrificial
nucleophiles directly attack and quench aldehyde groups, rendering RCS unable to
damage other biomolecules. 30,31
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One particularly promising subset of these aldehyde quenching agents includes
compounds containing a reactive thiol group. Examples include N-acetyl cysteine (NAC)
and several analogs,32 as well as other compounds containing cysteine such as s-allyl
cysteine, s-ethyl cysteine, s-methyl cysteine, and s-propyl cysteine.33 Also worthy of
note, are combination therapies involving thiol-containing compounds, such as the
combination ofN-acetyl cysteine and taurine,34 Of particular interest is the thiolcontaining small molecule compound D-Penicillamine
(3,3-dimethyl-D-cysteine, see Figure 4), which was
identified using a new screening process for aldehydequenching agents developed by Wondrak and colleagues

Figure 4 - Penicillamine structure . The
sulfh ydril (thiol) group readily reacts with

aldehydes, forming harml ess thiazolidine
derivatives.
(From PubChem)

at the University of Arizona Tucson. l D-Penicillamine
reacts with aldehyde groups to form benign thiazolidine

derivatives, which are easily cleared from the system. This reaction is shown in Figure 5.
The nucleophilic thiol group attacks the carbonyl carbon, freeing the oxygen as water and
forming a covalent linkage at the former site of the aldehyde. Penicillamine is used
therapeutically to treat a variety of pathologies, including rheumatoid arthritis (as a

R~
. '~;
. ~/1/~~

., .cOOH + H~O
'H

S

H,JC

C113

Figure 5 - Penicillamine al dehyde quenching reaction. The sulfhydril (th iol) group readily reacts with aldehydes , forming harmless thiazolidine
derivatives. (From Won drak et aL ' )

secondary medication), metal ion intoxication, cystinuria and Wilson's disease (copper
storage disease) . 35

9

Another similar small-molecule compound containing such a reactive thiol group
is N-(2-Mercaptopropionyl)glycine (MPG), which is also known by the names Acadione,
Capen, Captimer, Epatiol, Meprin (detoxicant), Mucolysin, Sutilan, Thiola,
Thiolpropionamidoacetic acid, Thiopronin, Thiopronine, Thiosol, Tioglis, Tiopronin, and
Vincol. MPG is used to treat cystinuria,36 arthritis/ 7 a variety of drug toxicities
associated with damaging carbonyls and reactive oxygen species (ROS)38,39, and also
demonstrates significant protection against ischemialreperfusion injury.4o It is also used
to scavenge ROS produced by ionizing radiation,41
as well as radiation-produced lipid peroxidation.

42
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Hypothesis
Such protective effects against lipid

peroxidation, together with the similar structure and
function to D-Penicillamine, an already proven
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Figure 6· MPG structure . The sulfhydril (!hiol) group
readily reacts with aldehydes, forming harmless
thiazolidine derivatives.
(From PubChem)

aldehyde quencher, have led to the hypothesis that MPG may offer significant aldehyde
quenching in atherosclerotic lesions and thus protection against carbonyl toxicity in
oxidized LDL.
Proposed Mechanism
MPG has been found to be a very effective free radical scavenger, and also iron
chelation and glutathione sparing have also been proposed as mechanisms behind the
protective effects conferred by MPG. 43 The susceptibility of its reactive sulfhydril group,
which is readily oxidized, makes it suited to a number of applications in ameliorating
oxidative damage. In particular, such thiol-containing small molecules, such as D-
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Penicillamine, have been demonstrated to be highly effective quenchers of reactive
aldehydes. Thus, the mechanism we propose as being most highly applicable to
detoxification of atherosclerotic plaques is that of aldehyde quenching, whereby its
sulfhydril group reacts directly with the aldehyde, forming thiazolidine derivatives which
are nonreactive.
Experimental Approach
To test the efficacy ofMPG as a protective agent, we have used the following

experimental model: Soft plaques obtained from carotid atheroma lesions are isolated
and homogenized in ethanol. Murine-derived 1774 macrophage-like cells, which have
been shown to respond to toxicity of atherosclerotic plaques44-46 , are exposed to varying
concentrations of this homogenate, both with and without the addition of MPG. Standard
culture viability assays are then used to determine the degree of protection conferred
against plaque-induced cell death.
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METHODS

Plaque Homogenization - Type I Homogenate
Samples of waste from percutaneous atherectomy procedures were obtained (IRB
#286.07) from Dr. Timothy Godshall, MD at University Hospital in Louisville, KY.
These were very dilute suspensions of atheroma lesion components suspended in saline.
The saline suspensions were centrifuged at 20,000g for 30 minutes. The pellet was then
weighed, suspended in 2ml 100% ethanol, and homogenized in a Wheaton glass-on-glass
homogenizer. After one hour of homogenization, the plaque suspension was decanted
off, and the remaining non-homogenizable components were weighed and then discarded.
The suspension was further homogenized using the tightest-fitting rod for the
homogenizer. After several hours of homogenization, the resulting suspension was added
to additional ethanol to make a IOmg/ml stock suspension.

Plaque Homogenization - Type II Homogenate
Atheromatous plaque samples from carotid endarterectomy surgical waste were
obtained immediately following procedures performed by Dr. Timothy Godshall, MD at
University Hospital in Louisville, KY. The entire atheroma that had been removed in the
endarterectomy was weighed after minimal drying to obtain the wet weight. This intact
piece was placed in a glass-on-glass Wheaton homogenizer along with I-2ml of 100%
ethanol, depending on the size of the atheroma. After one hour of homenization, the
plaque suspension was decanted off, and the remaining non-homogenizable components
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were weighed and then discarded. The suspension was further homogenized using the
tightest-fitting rod for the homogenizer. After several hours of homogenization, the
resulting suspension was added to additional ethanol to make a 5 to 100mg/ml stock
suspension, depending on how much material was isolated.

Plaque Homogenization - Type 111 Homogenate
In an effort to isolate more gelatinous plaque from the carotid endarterectomy
surgical waste samples without exposing other components to homogenization, the
gelatinous plaque components were scraped off using a scalpel. The isolated material
was then weighed and homomogenized as before, except no decanting/removal of nonhomogenizable material was necessary. We also attempted to maximize the
concentration of our stock solutions, giving between 75 and 100mg/ml, depending on
how m much material was isolated.

Cell Culture
1774 (Sigma #85011428) cells are derived from mouse monocyte/macrophage
cells and form semi-adherent layers when cultured. Cells were cultured in Dulbecco's
Modified Eagle's Medium (DMEM) with 2mM L-glutamine (Sigma #D6429) and 10%
Fetal Bovine Serum (FBS) at 37°C in a CO2 incubator.

Toxicity Assays
24 or 96-well (24-well Costar Clear, Coming #3473, or 96-well Costar black w/
clear bottom, Coming #3603) plates were seeded between 10% and 50%, depending on
the experiment, with 1774 cells and incubated at 37°C in a C02 incubator for 12h-24h,
depending on the experiment, at which point plaque homogenate, hydrogen peroxide and
MPG were added. Plates were then incubated for another 4h-24h, depending on the
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experiment, at which time the medium was changed and replaced with fresh medium
containing 10% AlamarBlue indicator. Following a 2h-4h incubation period, depending
on the experiment, the plate was read with a spectrofluorometer to determine cell
viability based on metabolic reduction of AlamarBlue.

AlamarBlue Viability Assay
AlamarBlue (ABD Serotec #BUF012B) was chosen because of its simplicity and
reliability. A 10% solution of AlamarBlue in normal culture medium is added to cells,
which under normal metabolic activity reduce the originally oxidized nonfluorescent blue
form of the indicator to the reduced fluorescent red form. 4 hours usually falls within the
linear phase of this reduction process, but readings at several different time points are
taken to verify that the reading chosen is within this range. Quantitation via the
spectrofluorometric plate reader ensures reliability and consistency. Viability is
expressed as the percent reduction of the indicator in test groups vs. the percent reduction
in controls.

Clonogenic Expansion Viability Assay
10cm polystyrene tissue culture
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incubated in DMEM at 37°C for 5 days.
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Medium was then removed, and plates were
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washed with phosphate-buffered saline
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0
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<»
(PBS). Cells were then fixed in a 50/50
Figure 7 - Example marked-up image from colony formation assay.
Stained and dried plates are filled with powdered sugar to provide
contrast and minimize reflections off the side of the plate. The pencil
tool in Adobe Photoshop was used to avoid miSSing or double--counting
colonies. The 50px circle also provided a means of ensuring all counted
colonies were above a certain size threshold. Counting was very fast,
reliable and consistent across olates usina this method .

PMSlMethanol solution for 2 minutes, and
then 100% Methanol for 10 minutes.
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Methanol was then removed, and the plates allowed to dry for 30 minutes. Cells were
then stained with Gentian Violet stain for 30 minutes, rinsed with tap water, and allowed
to air dry for 3 hours. Plates were then filled with powdered sugar to provide clean reads
and scanned on an HP flatbed scanner. Colonies were then counted in Adobe Photos hop
software, using the pencil tool with a 50pixel contrasting yellow circle to mark each
colony (Figure 7), which ensured accuracy in counting and provided a consistent
threshold for colony size.
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RESULTS

In order to verify plaque toxicity in our hands, a type I plaque homogenate (see
Methods section above for details) was made from dilute plaque gruel samples (see
Figure 8). The resulting homogenate was estimated to be 10mg/ml gruel, and 0.5% of
this added to test wells of a 24-well plate, giving a 50llg/ml final plaque concentration.
0.5% ethanol was used as a

Plaque Toxicity

vehicle control. There were 24
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AlamarBlue indicator. The
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o
Control
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AlamarBlue , the fluorescence reading was taken . Results are expressed as a percentage of the
viability of control cells, based upon the degree of AlamarBlue reduction .

AlamarBlue was added.
Mostly due to the fact that the

plate was too overgrown by the time the read was taken, not much toxicity could be seen,
even with our lOOIlM H2 0 2 positive control. To address these issues, the next assay
(Figure 9) was done using a 25% seeding density and more concentrated hydrogen
peroxide, to be sure the positive control was showing up. This resulted in significant
vehicle toxicity appearing from the ethanol, and virtual complete cell killing from the
1mM hydrogen peroxide.

16

As before, no significant
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Figure 9 - Plaque Toxicity Assay. A 24 well Costa r plate was seeded at 25% confluence
with J774 Cells. 24 hours later, plate was treated with 0.5% of the 10mg/ml plaque
homogenate. 0.5% Ethanol as a vehicle control and 100 IJM H20 2 as a positive control.
Six wells were used for each condition to provide replicates for improved statistical
significance. 24 hours after that, medium was exchanged for new medium containing
10% AlamarBl uB. After 4h incubation with AlamarBlu e, the fl uorescence rea ding was
taken. Results are expressed as a percentage of the viability of control cells, based upon
the degree of AlamarBlue red uction.

the result with higher ethanol and
plaque concentrations. A 24 well
Costar plate was seeded at 50%

confluence with 1774 Cells. 24 hours later, the plate was treated with 1% of the 10mg/ml
plaque homogenate. 1% Ethanol as a vehicle control and 1000 /lM H20 2 as a positive
control. Six wells were used for
each condition to provide replicates
for improved statistical
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Figure 10 - Plaque Toxicity Assay . A 24 well Costar plate was seeded at 50%
confluence with J774 Ce lls. 24 hours later, plate was treated with 0.5% of the
10mg/ml plaque homogenate. 0.5% Ethanol as a vehicle oontrol and 1000 ~M H, O,
as a positive control. Six wells were used for each condition to provide replicates for
improved sta tistical significa nce . 24 hours after that, medium was exchanged for new
medium containing 10% AlamarBlue. After 4h incubation with AlamarB lue , the
fl uorescence rea ding was taken. Results are expressed as a percentage of the
viability of control cells, based upon the degree of AlamarBlue reduction.

not very evident, but plate was quite overgrown by the time the reading was taken, again
confounding the results. Interestingly, when the plate was subsequently left in the
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incubator over the weekend, the cells in
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20% confluent. MPG was added in various concentrations, ranging from 5mM
to 150mM. Cells were incubated with MPG for 48h. and then a standard
AlamarBlue assay was performed , with a reading taken after 4h incubation.
Results are expressed as a percentage of the viability of control cells , based
upon the degree of AlamarBlue reduction .

toxicity assays (Figures 11 and 12) were
done in order to find the appropriate
levels for our model. In the case of

MPG, we were looking for minimal toxicity. A 96-well plate was seeded at 10%
confluence and allowed to incubate for 24h, at which point it was approximately 20%
confluent. MPG was added in various concentrations, ranging from 5mM to 150mM
(Figure 11). Cells were incubated with MPG for 48h, and then a standard AlamarBlue
Hydrogen Peroxide Toxicity

assay was performed, with a
reading taken after 4h
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Figure 12 - H 2 0 2 Toxicity Assay . H2 0 2 was added to 25% confluent 24-well plates in prediluted aliquots so 10~1 could be added to each well (wells contained 100~1 medium).
Concentrations ranged from 9-900IJM. 1QjJl water was added as a vehicle control . Then plates
were incubated for 20h, when we changed medium to add 10% Alamar blue. Reading was
taken 4 hours later. Results are expressed as a percentage of the viability of control cells,
based upon the degree of AlamarBlue reduction.

concentration for MPG.
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Due to earlier problems in finding the appropriate H 20 2 concentration for use as a
positive control, an H 20 2 toxicity assay was performed (Figure 12). H 20 2 was added to
25% confluent 24-well plates in pre-diluted aliquots so 101-1.1 could be added to each well
(wells contained 1001-1.1 medium), 101-1.1 water was added as a vehicle control to detect
possible effects from medium dilution. 24-well plates were used instead of 96-well so
that H 20

2

could be pipetted directly into each well, to avoid earlier problems with

depletion when using basins and a multichannel pipettor for the 96-well plates.
Following addition of toxin, plates were incubated for 20h, at which time the 1774 cells
were about 75% confluent in the most proliferative wells. Medium was then changed to
add 10% Alamar blue. The reading was taken 4 hours later. Despite quite a bit of
variability, an LDso of approximately 150l-l.M H 20 2 was apparent. In subsequent
experiments, we therefore used lOOI-l.M or 2001-tM, depending on the cell seeding density
of the experiment at hand.
Building on the experience gleaned from the previous assays, a larger scale
MPG Prevents Plaque Toxicity
140,---------------------------------------------------,

-e
c:

120
100

<3

80

>.

60

~

40

~

S

20

Control

EtOH

PS

P10

P20

P30

P40

PSO

H202

Figure 13 - MPG Experiment. 6 separate 96-well plates each contained a duplica te experiment. Results are from composi te data from all 6 plates ,
representing 24 indivdual tests for each condition. Error bars represent 95% confidence intervals. 1% Eth anol was used as a vehicle and plaque
concentrations of 5~9/ml through 50 ~ 9/m l were tested. Hyd rogen Peroxide was 200~ M . Results are expressed as a percentage of the viability of
control cells, based upon the degree of Ala marBlue reduction.
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experiment was done to test MPG alleviation of plaque toxicity using 6 96-well plates as
replicates. Each plate contained a complete set of assays, with 4 wells being allotted to
each condition (Figure 13). Fresh type II plaque homogenates were used (see Methods
section above for details), and plates were seeded at 20% confluence. Unfortunately this
still was not enough time, over the course of a 60+ hour experiment, to prevent the wells
from becoming overgrown. Thus results were once again rather obfuscated. Despite
these setbacks, due to the high number of replications a somewhat consistent trend could
be seen where evident toxicity at lower plaque concentrations was alleviated by the
addition ofMPG. Higher plaque concentrations proved inexplicably stimulatory to a
certain degree, but MPG rescue, and even stimulation in the case of controls, could be
seen across the board.
In order to see more toxicity, (Figure 14), 96-well plates were seeded at 25%
confluence, but a shorter overall time interval was used for the experiment. Three
replicate plates were done, and plaque concentrations ranged from 25-1001lg/ml. 200llM
MPG And Plaque Toxicity
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Figure 14 - 2.Sh Alamar Blu e 96-well plates were seeded at 25% confluence. Three replica te plates were done, and plaque concentrations
ranged from 25-100 ~ g/ml. Hydrogen Peroxi de wa s 20 0~M . 5mM MPG was added to groups labeled M. Results are expressed as a percentage
of the via bility of control cells , based upon th e degree of AlamarBlue reduction.

H 20 2 was used due to anticipated depletion in the multipipette basin. Toxins were added
just 8 hours after plate was seeded. If anything, wells treated with 5mM MPG fared
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worse, possibly due to the

Toxicity At Low Seeding Density

short pre-incubation time.
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Figure 15 - 96-weU plates were seeded at 5% confluence . Cells were incubated with AlamarBlue

for 3 hours before reading . Ethanol was 1% Wells were seeded at 5% confluence, grown for 24
hours and exposed to toxins for 48 hours. SmM MPG was added to groups labeled M. The MPG
group represents control wells with MPG only added. Hydrogen Peroxide was 200~M . Results
are expressed as a percentage of the viability of control cells. based upon the degree of
AlamarBlue reduction .

although the shorter-term

nature of the experiment (under 48h from seeding to read) was intended to alleviate that
problem.
The subsequent experiment (Figure 15) was done using an even lower seeding
density in an attempt
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Figure 16 - MPG Affect on Plaque Toxicity - 96-well plates were seeded at 10% confluence . Cells were
incubated with AlamarBlue for 3 hours before reading . Ethanol was 1% Wells were seeded at 10% confluence ,

grown for 24 hours and exposed to toxins for 48 hours. SmM MPG was added to groups labeled M. Hydrogen
Peroxide was 200~M . Results are expressed as a percentage of the viability of control cells , based upon the
degree of AlamarBlue reduction .

getting overgrown
before the assay was
finished. Cells were

incubated with AlamarBlue for 3 hours before reading. Ethanol was only 1% Wells
were seeded at 5% confluence, grown for 24 hours and exposed to toxins for 48 hours .
Despite the fact that toxicity was clearly evident, even in the vehicle group, MPG still
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apparently had no protective effect under this scenario. In fact, it seemed harmful,
probably considering the smaller number of cells while MPG concentration remained at
SmM .

In order to strike a happy middle ground between too confluent and not confluent
enough, we next seeded 3 96-well plates at 10% confluence, with a strict 24h regimen
between seeding, adding toxins, and taking the reading (Figure 16). Another factor was
new type III plaque homogenate (see Methods section above) . Unfortunately, the carotid
endarterectomy samples made available at the time were particularly devoid of soft
plaque components. Thus the samples extracted were extremely contaminated with
material from the vessel wall due to excessive scraping. Thus, the Img/ml plaque
concentration seems particularly intensive, yet actually reflects little plaque material.
The apparent stimulatory effects in plate 1 are more than likely due to an abnormally low
control group, due to problems with seeding density.
In order to see why we were not getting hardly any plaque toxicity with the new
samples, we performed two final assays
Plaque Toxicity Clonogenic Assay

- a colony formationlclonogenic
expansion assay and a very rigorous
AlamarBlue experiment using a 24-well
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Figure 17 - 10cm polystyrene tissue cultu re plates were seeded with 200 cells
each and incubated in DM EM at 3rC for 5 days. Cells we re then stained with
Gentia n Violet stai n for30 minutes. Plates were then scanned on an HP fl atbed
scanner. Colonies were counted in Adobe Photoshop software, using the
pencil tool with a SOpixel contrasting yellow circle to mark each colony. As
wi th all assays, error bars represent 95% confidence intervals.
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experimental system appears more sensitive than the AlamarBlue, which shows basically
no effect in a straightforward plaque toxicity assay (Figure 18).
Our fmal experiment was a test for plaque toxicity, using type III homogenates
obtained from fresh samples, which

Plaque Toxicity
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Figure 18 - Plaque Toxicity using type III homogenates.
Results are expressed
as a percentage of the viability of control cells. based upon the degree of
AlamarBlue reduction . Homogenate was 750~g/ml material - mostly non oxidized
lipid. Results are expressed as a percentage of the viability of control cells. based

upon the degree of AlamarBlue reduction.

cells/ml, giving approx. 10%
confluence for a 24-well plate. Wells

were close to SO% confluence at the time the cells were exposed, and as the ethanol
group shows, they were sufficiently resistant at this density. Sill of a 7Smg/ml
homogenate was added to SOOIlI medium in the plaque group and Smcl ethanol for that
group. Cells were exposed for 4 hours, treated with Alamarblue, then read 4h after that.
These are the most optimal conditions we arrived at, judging from all of our previous
experiments. The error bars outweigh the decreased viability, which is very slight to
begin with. While not very exciting, this is consistent with the experiments completed up
to this point. It seems like we have never been able to get decent toxicity out of the
atherosclerotic material from carotid endarterectomies, and the very first experiments we
did with more dilute samples were not much better.
Overall, our impression is that with these experimental models, toxicity is so
slight it gets buried in the noise with even the most doggedly consistent handling, unless
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incredibly low seeding densities are used, at which point we have problems with vehicle
and MPG toxicity.

24

DISCUSSION

Prospects of This Approach
After more than 10 experiments with this experimental system, its drawbacks are
obvious; there is a very fine line between vehicle toxicity and overgrown plates, giving a
very narrow (less than 48 hours) window of opportunity for experimentation. Therefore
the prospects of this approach appear somewhat limited. This appears to be a mainly
problem with the sample preparation, however. Variation in the samples procured,
together with changes in composition due to handling seem to outweigh the toxic effects
seen when oxidized lipids hit the plaque. The clonogenic assay seemed the most free
from experimental artifacts, and was apparently exquisitely sensitive to even the slightest
levels of growth stimulation and toxicity. Also, using extreme numbers of replicates, as
in our most successful experiment (Figure 13) enables slight effects to stand out from the
noise. Regardless, a new source of atheroma material is obviously necessary. In
previous successful experiments46 , 1.5g samples of purely soft plaque gruel were
obtainable. Such a source would apparently be necessary in order for such experiments
to succeed as they have done in the past, or better yet, artificially oxidized lipids.

Complimentary Approaches
Wang et al. have demonstrated the efficacy of using isolated LDL from plasma to
create OxLDL using CUS04. 44 Using such a reliable model for toxicity, in conjunction
with an assay for cell viability that does not involve redox reactions such as Trypan blue
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exclusion or Hoechst staining46 would probably be an excellent approach for future
experimentation, especially for preliminary screening experiments such as these,
although AlamarBlue seemed to work good enough in our hands for some of the
experiments. Even more appropriately for drug candidate screens, an approach like that
used by Wondrak et al. to use a screening method for direct, rapid detection of aldehyde
quenchers 1 would be an effective first step at arriving at a few good compounds worthy
of further testing.
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CONCLUSION

While our hypothesis remains somewhat in question, there have been some
indications that MPG may be protective (Figure 13). Also there are obvious toxicity
issues, depending on seeding density of the macrophages (Figures 14 and 15), so it by no
means represents the quintessential aldehyde-quenching drug. Despite the shortcomings
of this experimental approach however, the overall concept of using antioxidant and
carbonyl-quenching therapy to treat atherosclerosis is on solid ground, and is still an
active area ofresearch. 47 Combination treatment with other therapies appears to be
especially beneficial, both in regards to antioxidant therapi 4 ,26,34 and conventional
treatments with Statins and Omega-3 fattyacids 48 -51 . Thus, it seems that finding an
effective aldehyde-quenching agent for additional combined treatment of
atherosclerosis 45 ,46 would go a long way towards the elimination of heart disease as the
leading cause of death in developed countries.
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